Condition (MeSH)
Blastic Plasmacytoid Dendritic Cell Neoplasm
ClinicalTrials.gov lists 44 trials for Blastic Plasmacytoid Dendritic Cell Neoplasm or a narrower condition beneath it. Stemline Therapeutics, Inc. has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
44 of the 44 trials are tagged with Blastic Plasmacytoid Dendritic Cell Neoplasm itself; the rest are tagged with a narrower condition beneath it.
When did Blastic Plasmacytoid Dendritic Cell Neoplasm trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 6 |
| 2022 | 3 |
| 2021 | 1 |
| 2020 | 7 |
| 2019 | 4 |
| 2018 | 4 |
| 2017 | 4 |
| 2016 | 2 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 11 trials still running at the 2026-10-09 snapshot; registered median of 43 months across 24 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Blastic Plasmacytoid Dendritic Cell Neoplasm trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 17 |
| Phase 1/2 | 6 |
| Phase 2 | 13 |
| Not applicable | 2 |
| Observational | 6 |
How many Blastic Plasmacytoid Dendritic Cell Neoplasm trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 13 |
| Active, not recruiting | 7 |
| Completed | 13 |
| Terminated | 7 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Blastic Plasmacytoid Dendritic Cell Neoplasm trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Stemline Therapeutics, Inc. | 3 |
| Chongqing Precision Biotech Co., Ltd | 2 |
| Mustang Bio | 2 |
| AbbVie | 1 |
| Beijing Biotech | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Blastic Plasmacytoid Dendritic Cell Neoplasm? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 9 |
| Tagraxofusp | 7 |
| Thiotepa | 3 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 9 |
| Venetoclax 600 | 5 |
| Total Body Irradiation | 5 |
| Bone marrow aspiration | 4 |
| HD- Methotrexate (MTX) | 4 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Blastic Plasmacytoid Dendritic Cell Neoplasm trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Infections and infestations - Other | 49 | 1 |
| Mucositis oral | 47 | 1 |
| PNEUMONIA | 35 | 1 |
| FEBRILE NEUTROPENIA | 26 | 1 |
| Capillary leak syndrome | 20 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Blastic Plasmacytoid Dendritic Cell Neoplasm? (1)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm. | Cancer | 2026 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.